HomeQuestion

Does treating CLL reduce the risk of non-melanoma skin cancers?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?

Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?

If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

How would you treat AML in a pregnant patient at 12 weeks' gestation?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

Does treating CLL reduce the risk of non-melanoma skin cancers? | Mednet